We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Novartis (NVS) Q1 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Novartis (NVS - Free Report) to post quarterly earnings of $2.11 per share in its upcoming report, which indicates a year-over-year decline of 7.5%. Revenues are expected to be $13.56 billion, up 2.5% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific Novartis metrics that are commonly monitored and projected by Wall Street analysts.
The consensus among analysts is that 'Revenues- Oncology- Tafinlar + Mekinist- Total' will reach $555.25 million. The estimate suggests a change of +0.6% year over year.
It is projected by analysts that the 'Revenues- Other revenues' will reach $459.04 million. The estimate points to a change of +18.6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Oncology- Kisqali- Total' will likely reach $1.47 billion. The estimate indicates a change of +54% from the prior-year quarter.
Analysts expect 'Revenues- Immunology- Cosentyx- Total' to come in at $1.65 billion. The estimate suggests a change of +7.5% year over year.
According to the collective judgment of analysts, 'Revenues- Oncology- Tasigna- US' should come in at $39.24 million. The estimate indicates a year-over-year change of -80.1%.
Analysts forecast 'Revenues- Oncology- Promacta/Revolade- US' to reach $58.23 million. The estimate suggests a change of -79.8% year over year.
Based on the collective assessment of analysts, 'Revenues- Immunology- Cosentyx- US' should arrive at $891.17 million. The estimate points to a change of +9.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Cardiovascular- Entresto- US' of $220.89 million. The estimate points to a change of -81.1% from the year-ago quarter.
Analysts predict that the 'Revenues- Oncology- Tasigna- ROW' will reach $121.70 million. The estimate suggests a change of -32.4% year over year.
The consensus estimate for 'Revenues- Oncology- Tafinlar + Mekinist- ROW' stands at $372.67 million. The estimate points to a change of +8.3% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Oncology- Promacta/Revolade- ROW' reaching $161.68 million. The estimate points to a change of -37.3% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Immunology- Cosentyx- ROW' at $757.57 million. The estimate indicates a change of +5.4% from the prior-year quarter.
Over the past month, shares of Novartis have returned -2.3% versus the Zacks S&P 500 composite's +9.7% change. Currently, NVS carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Unveiling Novartis (NVS) Q1 Outlook: Wall Street Estimates for Key Metrics
Wall Street analysts expect Novartis (NVS - Free Report) to post quarterly earnings of $2.11 per share in its upcoming report, which indicates a year-over-year decline of 7.5%. Revenues are expected to be $13.56 billion, up 2.5% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific Novartis metrics that are commonly monitored and projected by Wall Street analysts.
The consensus among analysts is that 'Revenues- Oncology- Tafinlar + Mekinist- Total' will reach $555.25 million. The estimate suggests a change of +0.6% year over year.
It is projected by analysts that the 'Revenues- Other revenues' will reach $459.04 million. The estimate points to a change of +18.6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Oncology- Kisqali- Total' will likely reach $1.47 billion. The estimate indicates a change of +54% from the prior-year quarter.
Analysts expect 'Revenues- Immunology- Cosentyx- Total' to come in at $1.65 billion. The estimate suggests a change of +7.5% year over year.
According to the collective judgment of analysts, 'Revenues- Oncology- Tasigna- US' should come in at $39.24 million. The estimate indicates a year-over-year change of -80.1%.
Analysts forecast 'Revenues- Oncology- Promacta/Revolade- US' to reach $58.23 million. The estimate suggests a change of -79.8% year over year.
Based on the collective assessment of analysts, 'Revenues- Immunology- Cosentyx- US' should arrive at $891.17 million. The estimate points to a change of +9.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Cardiovascular- Entresto- US' of $220.89 million. The estimate points to a change of -81.1% from the year-ago quarter.
Analysts predict that the 'Revenues- Oncology- Tasigna- ROW' will reach $121.70 million. The estimate suggests a change of -32.4% year over year.
The consensus estimate for 'Revenues- Oncology- Tafinlar + Mekinist- ROW' stands at $372.67 million. The estimate points to a change of +8.3% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Oncology- Promacta/Revolade- ROW' reaching $161.68 million. The estimate points to a change of -37.3% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Immunology- Cosentyx- ROW' at $757.57 million. The estimate indicates a change of +5.4% from the prior-year quarter.
View all Key Company Metrics for Novartis here>>>Over the past month, shares of Novartis have returned -2.3% versus the Zacks S&P 500 composite's +9.7% change. Currently, NVS carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .